Cargando…
Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis
PURPOSE: In-vivo quantification of tumor uptake of 89-zirconium ((89)Zr)-labelled monoclonal antibodies (mAbs) with PET provides a potential tool in strategies to optimize tumor targeting and therapeutic efficacy. A specific challenge for (89)Zr-immuno-PET is low tumor contrast. This is expected to...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647131/ https://www.ncbi.nlm.nih.gov/pubmed/31209514 http://dx.doi.org/10.1007/s00259-019-04377-6 |
_version_ | 1783437662513790976 |
---|---|
author | Jauw, Yvonne W. S. Bensch, Frederike Brouwers, Adrienne H. Hoekstra, Otto S. Zijlstra, Josée M. Pieplenbosch, Simone Schröder, Carolien P. Zweegman, Sonja van Dongen, Guus A. M. S. Menke-van der Houven van Oordt, C. Willemien de Vries, Elisabeth G. E. de Vet, Henrica C. W. Boellaard, Ronald Huisman, Marc C. |
author_facet | Jauw, Yvonne W. S. Bensch, Frederike Brouwers, Adrienne H. Hoekstra, Otto S. Zijlstra, Josée M. Pieplenbosch, Simone Schröder, Carolien P. Zweegman, Sonja van Dongen, Guus A. M. S. Menke-van der Houven van Oordt, C. Willemien de Vries, Elisabeth G. E. de Vet, Henrica C. W. Boellaard, Ronald Huisman, Marc C. |
author_sort | Jauw, Yvonne W. S. |
collection | PubMed |
description | PURPOSE: In-vivo quantification of tumor uptake of 89-zirconium ((89)Zr)-labelled monoclonal antibodies (mAbs) with PET provides a potential tool in strategies to optimize tumor targeting and therapeutic efficacy. A specific challenge for (89)Zr-immuno-PET is low tumor contrast. This is expected to result in interobserver variation in tumor delineation. Therefore, the aim of this study was to determine interobserver reproducibility of tumor uptake measures by tumor delineation on (89)Zr-immuno-PET scans. METHODS: Data were obtained from previously published clinical studies performed with (89)Zr-rituximab, (89)Zr-cetuximab and (89)Zr-trastuzumab. Tumor lesions on (89)Zr-immuno-PET were identified as focal uptake exceeding local background by a nuclear medicine physician. Three observers independently manually delineated volumes of interest (VOI). Maximum, peak and mean standardized uptake values (SUV(max), SUV(peak) and SUV(mean)) were used to quantify tumor uptake. Interobserver variability was expressed as the coefficient of variation (CoV). The performance of semi-automatic VOI delineation using 50% of background-corrected AC(peak) was described. RESULTS: In total, 103 VOI were delineated (3–6 days post injection (D3-D6)). Tumor uptake (median, interquartile range) was 9.2 (5.2–12.6), 6.9 (4.0–9.6) and 5.5 (3.3–7.8) for SUV(max), SUV(peak) and SUV(mean.) Interobserver variability was 0% (0–12), 0% (0–2) and 7% (5–14), respectively (n = 103). The success rate of the semi-automatic method was 45%. Inclusion of background was the main reason for failure of semi-automatic VOI. CONCLUSIONS: This study shows that interobserver reproducibility of tumor uptake quantification on (89)Zr-immuno-PET was excellent for SUV(max) and SUV(peak) using a standardized manual procedure for tumor segmentation. Semi-automatic delineation was not robust due to limited tumor contrast. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-019-04377-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6647131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-66471312019-08-06 Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis Jauw, Yvonne W. S. Bensch, Frederike Brouwers, Adrienne H. Hoekstra, Otto S. Zijlstra, Josée M. Pieplenbosch, Simone Schröder, Carolien P. Zweegman, Sonja van Dongen, Guus A. M. S. Menke-van der Houven van Oordt, C. Willemien de Vries, Elisabeth G. E. de Vet, Henrica C. W. Boellaard, Ronald Huisman, Marc C. Eur J Nucl Med Mol Imaging Original Article PURPOSE: In-vivo quantification of tumor uptake of 89-zirconium ((89)Zr)-labelled monoclonal antibodies (mAbs) with PET provides a potential tool in strategies to optimize tumor targeting and therapeutic efficacy. A specific challenge for (89)Zr-immuno-PET is low tumor contrast. This is expected to result in interobserver variation in tumor delineation. Therefore, the aim of this study was to determine interobserver reproducibility of tumor uptake measures by tumor delineation on (89)Zr-immuno-PET scans. METHODS: Data were obtained from previously published clinical studies performed with (89)Zr-rituximab, (89)Zr-cetuximab and (89)Zr-trastuzumab. Tumor lesions on (89)Zr-immuno-PET were identified as focal uptake exceeding local background by a nuclear medicine physician. Three observers independently manually delineated volumes of interest (VOI). Maximum, peak and mean standardized uptake values (SUV(max), SUV(peak) and SUV(mean)) were used to quantify tumor uptake. Interobserver variability was expressed as the coefficient of variation (CoV). The performance of semi-automatic VOI delineation using 50% of background-corrected AC(peak) was described. RESULTS: In total, 103 VOI were delineated (3–6 days post injection (D3-D6)). Tumor uptake (median, interquartile range) was 9.2 (5.2–12.6), 6.9 (4.0–9.6) and 5.5 (3.3–7.8) for SUV(max), SUV(peak) and SUV(mean.) Interobserver variability was 0% (0–12), 0% (0–2) and 7% (5–14), respectively (n = 103). The success rate of the semi-automatic method was 45%. Inclusion of background was the main reason for failure of semi-automatic VOI. CONCLUSIONS: This study shows that interobserver reproducibility of tumor uptake quantification on (89)Zr-immuno-PET was excellent for SUV(max) and SUV(peak) using a standardized manual procedure for tumor segmentation. Semi-automatic delineation was not robust due to limited tumor contrast. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-019-04377-6) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-06-17 2019 /pmc/articles/PMC6647131/ /pubmed/31209514 http://dx.doi.org/10.1007/s00259-019-04377-6 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Jauw, Yvonne W. S. Bensch, Frederike Brouwers, Adrienne H. Hoekstra, Otto S. Zijlstra, Josée M. Pieplenbosch, Simone Schröder, Carolien P. Zweegman, Sonja van Dongen, Guus A. M. S. Menke-van der Houven van Oordt, C. Willemien de Vries, Elisabeth G. E. de Vet, Henrica C. W. Boellaard, Ronald Huisman, Marc C. Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis |
title | Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis |
title_full | Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis |
title_fullStr | Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis |
title_full_unstemmed | Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis |
title_short | Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis |
title_sort | interobserver reproducibility of tumor uptake quantification with (89)zr-immuno-pet: a multicenter analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647131/ https://www.ncbi.nlm.nih.gov/pubmed/31209514 http://dx.doi.org/10.1007/s00259-019-04377-6 |
work_keys_str_mv | AT jauwyvonnews interobserverreproducibilityoftumoruptakequantificationwith89zrimmunopetamulticenteranalysis AT benschfrederike interobserverreproducibilityoftumoruptakequantificationwith89zrimmunopetamulticenteranalysis AT brouwersadrienneh interobserverreproducibilityoftumoruptakequantificationwith89zrimmunopetamulticenteranalysis AT hoekstraottos interobserverreproducibilityoftumoruptakequantificationwith89zrimmunopetamulticenteranalysis AT zijlstrajoseem interobserverreproducibilityoftumoruptakequantificationwith89zrimmunopetamulticenteranalysis AT pieplenboschsimone interobserverreproducibilityoftumoruptakequantificationwith89zrimmunopetamulticenteranalysis AT schrodercarolienp interobserverreproducibilityoftumoruptakequantificationwith89zrimmunopetamulticenteranalysis AT zweegmansonja interobserverreproducibilityoftumoruptakequantificationwith89zrimmunopetamulticenteranalysis AT vandongenguusams interobserverreproducibilityoftumoruptakequantificationwith89zrimmunopetamulticenteranalysis AT menkevanderhouvenvanoordtcwillemien interobserverreproducibilityoftumoruptakequantificationwith89zrimmunopetamulticenteranalysis AT devrieselisabethge interobserverreproducibilityoftumoruptakequantificationwith89zrimmunopetamulticenteranalysis AT devethenricacw interobserverreproducibilityoftumoruptakequantificationwith89zrimmunopetamulticenteranalysis AT boellaardronald interobserverreproducibilityoftumoruptakequantificationwith89zrimmunopetamulticenteranalysis AT huismanmarcc interobserverreproducibilityoftumoruptakequantificationwith89zrimmunopetamulticenteranalysis |